TrialsgrambêtaRCTs are beautiful
ESC Congress 2026Présenté lun. 31 août · 08:40 UTC+2Hot Line 10Tous les essais Hot Line →

SyncAV PMT

2026

SyncAV Post-Market Trial

In 1,288 CRT recipients with left bundle branch block, dynamic AV-delay optimisation did not reduce the reduction in LV end-systolic volume at 12 months compared with a fixed AV delay.

Résultat

Critère principal: Change in left ventricular end-systolic volume from baseline to 12 months (continuous), compared between arms

Left ventricular end-systolic volume at 12 months did not differ (P = 0.054), nor did the proportion of responders with a fall of at least 15% (P = 0.16). Paced QRS was shorter with the algorithm (123 vs 138 ms; P < 0.0001) and atrial fibrillation lasting more than 10 days was less frequent (2.0% vs 4.4%; P = 0.03). Mortality 2.1% vs 2.4%. In the exploratory half with a PR interval of 185 ms or more, the clinical composite ran 10.3% vs 21.5% (P = 0.006).

Publication originale
Sous-thème
CRT optimisation
Schéma
Prospective, international multicentre, randomised (1:1), open-label post-market trial sponsored by Abbott; patients receiving a new Abbott quadripolar CRT system randomised 2–6 weeks after successful implant to SyncAV dynamic atrioventricular-delay optimisation programmed ON (offset selected by QRS narrowing) versus a fixed nominal AV delay; follow-up at 3, 6 and 12 months; started October 2019, primary completion estimated mid-2026.
Pertinence
Important: l’un des piliers parmi d’autres.
Source
Varma N, Mont L, Zareba W, et al. Presented at ESC Congress 2026, Hot Line 10, 31 August.

Discussion et critique

An algorithm that keeps fusion pacing as the PR interval wanders produced the narrower paced QRS it was designed for and no better remodelling at a year: the electrical target moved, the ventricle did not. The primary endpoint at P = 0.054 will be quoted as a near miss; it is a miss, and the responder analysis agrees. What may survive is the subgroup with a PR interval of 185 ms or longer, where fixed programming loses fusion and the clinical composite halved: half the cohort, entirely exploratory, and the trial's own hypothesis for the next one.